Richter Syndrome: From Molecular Pathogenesis to Druggable Targets

Medicine and Dentistry

• B Lymphocyte Receptor 100%
• Molecular Pathology 100%
• B-Cell Chronic Lymphocytic Leukemia 66%
• Diffuse Large B-Cell Lymphoma 66%
• Clinical Trial 33%
• T Cell 33%
• Programmed Cell Death 33%
• Cell Cycle 33%
• Cytotoxicity 33%
• Rituximab 33%
• Cell Proliferation 33%
• Cancer 33%
• Xenograft 33%
• Personalized Medicine 33%
• Hyperactivation 33%
• Aggressive Lymphoma 33%
• Chemoimmunotherapy 33%
• Autoantigen 33%
• Cancer Inhibition 33%
• Programmed Death-Ligand 1 33%
• DNA Damage Response 33%
• Cyclin Dependent Kinase Inhibitor 2A 33%
• Immune Checkpoint Inhibitor 33%
• Systemic Juvenile Idiopathic Arthritis 33%
• Protein Kinase B 33%

Keyphrases

• Druggable Targets 100%
• Molecular Pathogenesis 100%
• Richter Syndrome 100%
• Chronic Lymphocytic Leukemia 25%
• Bcl-2 Inhibitor 25%
• C-Myc 12%
• Genetic Lesions 12%
• Tumor Protein p53 (TP53) 12%
• Diffuse Large B-cell Lymphoma (DLBCL) 12%
• Altered Expression 12%
• T Cells 12%
• Notch1 12%
• Molecular Mechanism 12%
• Non-covalent 12%
• Aggressive Lymphoma 12%
• Vulnerability 12%
• B-cell Receptor Signaling 12%
• De Novo Diffuse Large B-cell Lymphoma 12%
• B Cell Receptor 12%
• Anti-CD20 Antibody 12%
• Autoantigen 12%
• Molecular Features 12%
• AKT Pathway 12%
• Hyperactivity 12%
• Apoptotic Cells 12%
• DNA Damage Response 12%
• Immune Checkpoint 12%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 12%
• Stereotyped B-cell Receptors 12%
• Molecular Targets 12%
• Precision Medicine 12%
• Chemoimmunotherapy 12%
• Notch1 Signaling 12%
• Tumor Suppression 12%
• Early Phase Clinical Trials 12%
• Programmed Death-ligand 1 (PD-L1) 12%
• Unmet Medical Need 12%
• Immune Checkpoint Inhibitors 12%
• Secondary Malignancy 12%
• ROR1 12%
• Medicine Therapy 12%
• Mouse Xenograft Model 12%
• Resistance to Cytotoxicity 12%
• Direct Transformation 12%
• BTK Inhibitor 12%
• Overreactivity 12%

Biochemistry, Genetics and Molecular Biology

• B-Cell Receptor 100%
• B Cell 66%
• Cytotoxicity 33%
• Cell Proliferation 33%
• T Cell 33%
• Genetics 33%
• Clinical Trial 33%
• DNA Damage Response 33%
• Mouse Model 33%
• Autoantigen 33%
• Cell Cycle 33%
• Rituximab 33%
• Immune Checkpoints 33%
• PD-L1 33%
• Programmed Cell Death 33%
• Protein Kinase B 33%
• Cyclin Dependent Kinase Inhibitor 2A 33%
• Immune Checkpoint Inhibitor 33%